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Abstract
Advanced age is one indicator of likely immune dysfunction. As worldwide, the global population contains progressively
more and more older individuals there is likelihood of an increased prevalence and incidence of infectious diseases due
to common and emergent pathogens. The resultant increase in mortality and morbidity would be matched by the risk of
functional decline and disability. Maintaining immune function at a plateau throughout life may therefore be associated
with considerable cost savings. The aim of improving immune function in older individuals may be achieved through
considering a therapeutic approach to rejuvenate, stimulate or support the indigenous immune system to perform in
a more optimal manner. In terms of cost effectiveness a therapeutic approach may prove difficult because of issues
associated with; identifying those who would benefit the most from this treatment, identifying the type of treatment
which would suit them and identifying whether the treatment was successful. The alternative of supporting or
providing a stronger stimulus through vaccination, whilst more cost effective, may be a more valuable option in
the short term. Both approaches will be addressed in this review.
Background
The slow and inexorable increase in the number of older
individuals worldwide over the next few decades will have
a considerable impact on healthcare services and also on
the epidemiology of transmissible and non transmissible
diseases. The latter are expected to reach unprecedent
rates [1, 2]. Those over the age of 65 currently travel more
frequently and more widely than either their parents or
grandparents [3]. They are also physically more active
than their counterparts a few decades ago and these fac-
tors will play a role in changing the epidemiology of dis-
ease. Another factor contributing to the problem is the
way the globe is now so closely networked that any indi-
vidual or any pathogen may cross the planet within hours,
as has been reported recently with H5N1, H1N1, MERS,
SRAS, Chikungunya, and other emerging pathogens out-
breaks [4, 5]. Also we must include into this algorithm the
increased vulnerability in part, due to the decline in
immune functioning in this older group. All together,
these factors will contribute to shift in the pattern of com-
mon and emerging infectious diseases.
Pre-emptive action is required to preserve this growing
sector of the general population and to keep them func-
tionally independent in their daily lives. Whilst vaccin-
ation is one of the most effective medical interventions
ever introduced and prevents millions of cases of infec-
tions worldwide every year, vaccines are often thought to
be less effective in providing protection in this older
section of society. One major reason for this statement
is again the decline seen in effective immunity in this
population. Studies from several countries have reported
that the immune system declines with age indicating the
global nature of this problem, but there are fewer studies
which have sought the solution to this problem. One
approach has been to try to restore immunity within this
population to something akin to that seen in younger
individuals. Another has been to take a more practical
approach believing that a weaker immune system may be
provoked into providing a response if the stimulus is con-
siderably strengthened and enhanced. Both approaches
will be discussed in this review.
Recipients
Identification of individuals who would receive specific
therapy to restore their immune function is very challen-
ging. The main issue is to how to recognise an individual
who is not immune competent enough to deal with new
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and/or common antigens but who still seems healthy.
This has been approached in a very pragmatic manner
by some policy makers. To the outsider, it would appear
that decisions have been made in the following way
(i) Immune senescence or immune insufficiency is
associated with old age.
(ii)Individuals are considered old when they reach a
specific age, frequently thought of as around 60-65
in developed and developing countries because after
this age people receive benefits and concessions.
(iii)Since individuals who are over 65 are old they must
have dysfunctional immune systems.
(iv)So everyone over 65 should be offered vaccines
which are supplemented with adjuvants or
increased amounts of antigen to compensate for
immune decline.
Our issue with such a dogmatic approach is with the
idea of using precisely defined criteria, which in this case
is age, with immune dysfunction which is imprecisely
defined and only weakly linked with the ageing process.
What we believe to be required is a means of grading
immune functioning quantitatively and qualitatively [6].
Appropriate immune functioning
One of the problems with the immune system is that its
action is invisible and hence not easy to quantify. The
immune system provides protection from a series of
potential pathogens which we may encounter daily.
Their failure to cause disease is neither recognised nor
perceived. We have no way of counting the rate of our
exposure to pathogenic organisms and we only become
aware of the role of the immune system in our survival
when it is lacking or through the incidence of some spe-
cific diseases. Of course, individuals who are immune
deficient show an increased susceptibility to opportunis-
tic pathogens, poorer responses to vaccination, and
greater likelihood of morbidity and mortality associated
with infections. However, infections are not restricted to
those individuals, and healthy people with normal func-
tioning immunity also suffer from viral, bacteria, fungal
and parasitic infections.
As a consequence, and in comparison to organs such
as the skin where there is greater visibility of age-related
changes and methods for measuring them, neither
device nor method exists for assessing an individual’s
overall immune capacity and its rate of change. People
can be identified after vaccination with for example in-
fluenza antigen whose responses are less than adequate
making them liable to infection with the corresponding
virus strains. But this is one of a few cases following
vaccination where immunity is associated with an a priori
defined amount of specific antibody. Clinicians wishing to
measure immune competency may call for full blood
counts, T and B cell counts including their subsets, the
quantity of immunoglobulin in the serum and the pres-
ence of specific antibodies. Whilst this provides a general
overview of some of the elements of the immune system it
does not provide a functional measure of the capacity of
an individual to respond to a specific threat unless values
are well below the normal boundaries. An older individual
with immune parameters within the normal levels who
may have immune dysfunction would thus not be easily
identified. So any attempt to restore immunity in older
individuals first requires that simple methods of assess-
ment are derived to determine the effectiveness of the
process as a whole. These assessment methods must (i) be
function related; (ii) must be relatively rapid in providing
results; (iii) must be relatively non-invasive; and (iv)
require relatively simple forms of equipment.
In view of these guidelines it becomes apparent that
such measures as improved responses to vaccination
(against for example untreated age matched controls) or
reduction in the incidence of infection may be accept-
able as measures in the long-term but in the short-term
there needs to be some more immediate indicators.
Contributing factors to immune decline
Change in the fat content of tissues varies between indi-
viduals and over the life course. Overall, the body com-
position changes with age and there is a gradual loss of
lean body mass combined with the accumulation of fatty
tissue at different locations [7, 8]. Nowhere is this more
apparent than in the primary lymphoid organs where
the increase in adipocyte numbers leads to macroscopic
changes in the colour of these tissues, and the loss of
cellular niches and a gradual decline in their overall
function as primary generator of lymphocytes. Reduction
in the active area of thymus through fat accumulation
leads to a loss of an adequate productive environment
for thymocyte development and a consequent reduction
in the thymic output [9–11]. Similarly the increase in
the amount fat in the bone marrow with age as shown
by its change in colour from red to yellow alters the abil-
ity of the marrow to provide a supportive framework for
the production of B cells [12]. In addition to change in
the rate of production of new lymphocytes, immune de-
cline may also be linked to the longevity of specific
lymphocyte clones. This is a complex process; since
lymphocytes have a limited replicative lifespan and the
faster more of them reach the limit through responding
to antigen the more rapidly will be the onset of func-
tional holes in the repertoire and an inability to respond
to a specific challenge.
Adipose tissue expansion with age is also thought of as
a major source of inflammation that has a marked influ-
ence on systemic metabolism and contributes to the
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onset of devastating conditions such as insulin resistance,
type-2 diabetes, and cardiovascular disorders [13]. How-
ever, during the development of diet-induced obesity or
age-associated adiposity, immunocompetent cells infiltrate
and proliferate in the adipose tissue. Cells of the adaptive
immune system, including T and B cells, thus contribute
significantly to generate chronic and lowgrade inflamma-
tion. Lymphocytes regulate recruitment of innate immune
cells into fat tissue, and hence produce a large panel of
pro-inflammatory cytokines [14]. This influences the
helpful-to-harmful inflammatory balance that, in turn,
contributes to the age-associated functional decline in the
immune system and the onset of conditions affecting
health and well-being [15].
Approaches to restoration or stimulating immune
function
In considering older individuals we may choose to
improve their immunity specifically, non-specifically in
the periphery, or consider rejuvenating their immune
system through the reversal of the decline observed in
their primary lymphoid organs. Each of these will be
dealt with in turn.
Restoration through enhanced stimulation or metabolic
manipulation
Nutrition
One of the issues which is often overlooked is the
considerable amount of energy required to undertake an
immune response. Naïve T cells which are normally in a
close to quiescent state must shift to activation by chan-
ging their metabolism after encountering antigen. Suc-
cessful activation is followed by an increased uptake of
nutrients, increased mitochondrial oxidative phosphoryl-
ation and the cells metabolism becomes predominantly
glycolytic. This shift presages the demand for energy and
cell components precursors required for proliferation
[16]. For many older individuals the necessary energy to
make a successful immune response may be lacking
because of either an inadequate diet or the change in the
permeability of the gut to specific elements. Insufficient
energy to deliver an immune response which is adequate
may be due to a number of simple reasons. For example
one previous study indicated a significant association be-
tween inadequate calorie intake and being underweight
in older people with deficient or poorly functioning den-
tition [17]. Studies in which the diet of older individuals
was supplemented, with an energy source and trace
elements revealed that treated individuals could produce
a greater response to influenza [18–21] and pneumococ-
cal vaccination [22, 23]. Changes in the permeability of
the gut alter the uptake of trace elements such as zinc.
The critical role of zinc for the immune system comes
from studies on zinc deficient individuals who may have
thymic atrophy, lymphopenia and recurrent infection
[24] however studies on zinc supplementation of the diet
of older individuals has failed to provide a conclusive re-
sult which would be beneficial to vaccine practitioners
[25]. The immunomodulatory role and the potential im-
mune enhancer property of vitamin D have been
highlighted recently. Studies which have looked at ability
of vitamin D supplements to improve the effectiveness
of vaccines provide conflicting information [26].
Rapamycin
The fungus Streptomyces hygroscopicus found in a soil
sample from Easter Island was shown to produces a
macrolide compound named rapamycin which was sub-
sequently found to inhibit proliferation of mammalian
cells and to possess immunosuppressive properties.
These properties led to it being approved by the Food
and Drug Administration in the United States for cancer
therapy such as renal cell carcinoma. The normal oral
dose for cancer patients would be in the region of 10 mg
a day. Later experiments in mouse models suggested
that at lower doses rapamycin could improve response
to influenza antigen possibly by inhibiting the formation
of germinal centres thus reducing the production of high
affinity antibodies but permitting the production of
lower affinity antibody and increasing the presence of
influenza-specific IgM antibodies [27]. These results
prompted trials in humans where recipients received
0.5 mg daily, or 5 or 20 mg weekly or placebo. After a
six-week course and a two-week gap the recipients were
vaccinated with the trivalent influenza vaccine. Those in
the treatment group showed considerable and significant
improvement in their immune response when compared
to those in the placebo group [28].
Adjuvants
One approach to restoring an effective immune response
to a vaccine antigen in older individuals and to ensure
adequate levels of protection has been to introduce an
adjuvant in the vaccine composition [29]. The classic
adjuvant containing aluminium salts has more recently
been replaced by oil in water emulsions which have been
used with great effect to promote a response to a zoster
subunit vaccine for example. However success with
adjuvants is a double edged sword. In one study of those
who received the adjuvanted herpes zoster subunit vac-
cine 81.5% showed injection site reactions and 66.1%
showed systemic reactions [30]. The mechanisms of ac-
tion of adjuvants are not entirely clear yet. It is thought
that they may in part act as depots of antigen prolonging
it presence in the periphery, or interact with pattern
recognition elements on accessory cells, or stimulate a
local inflammatory response so bringing more cells to
the area [29]. Whilst adjuvants have been shown to be
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effective in improving vaccine related responses in older
adults their use may be limited to vaccines which are
given infrequently. For example it may not be wise to
vaccinate an older individual every year for 30 years
(from age 65 to 95) with an influenza vaccine supple-
mented with adjuvant. Used in such a way this may drive
all specific clones of responding cells to reach their repli-
cative limit sooner which may prove counterproductive.
Increased amounts of antigen
Increasing the amount of antigen within the dose of vac-
cine has been also shown to improve the response in
older individuals, but not in a directly correlative man-
ner. So, giving for example ten times the antigen dose
will not produce a ten-fold increase in the immune
response to the corresponding vaccine antigen. Vaccines
with increased amounts of antigen include the influenza
vaccine with four times the amount of antigen than the
standard-dose vaccine (60 μg instead of 15 μg of haem-
agglutinin antigen for each of the three influenza A/
H1N1, A/H3N2 and B strains) and Zostavax a live atten-
uated varicella zoster virus vaccine administered only to
seniors, which contains more than 14 times the number
of plaque forming units than the standard varicella
vaccine recommended for children. This latter vaccine
boosts immunity to the varicella zoster virus in older in-
dividuals and significantly reduces the incidence of
herpes zoster and post-herpetic neuralgia [31].
Specific rejuvenation
Adoptive transfer of specific clones
One of the issues which is often considered to be a
major problem in older people is latent virus infections.
Control of these viruses is present throughout life but as
we age this control begins to wain as seen with those
harbouring the varicella zoster virus (human herpes
virus 3 or HHV-3) who become susceptible to increased
bouts of shingles the disease associated with herpes zos-
ter and an increase in the prevalence of post herpetic
neuralgia with age. Control of cytomegalovirus (CMV or
HHV-5) has also been shown to decline with age with
the appearance of detectable virus in the urine of older
people [32]. Studies using the adoptive transfer of CMV
specific CD8 T cells showed that overt disease could be
controlled in individuals post-transplant [33, 34]. Whilst
this treatment is still at an early phase and unlikely to be
offered to older individuals in the near future more re-
cent work suggests that virus specific T cells could be
generated from autochthonous stem cells [35].
Non-specific rejuvenation
Blood transfusion
Heterochronic parabiosis; the surgical joining of two
animals of different ages such that they have a common
blood circulation has been used successfully in the past to
identify means of ameliorating age related changes in the
cardiac system [36] and in cognitive function [37]. Experi-
ments to modify the immune system of the older partner of
the parabiont by an extrinsic factor from the younger para-
biont revealed that whilst pre-T cells from either parabiont
could seed the opposing thymus and undergo thymopoiesis
there was no reversal of thymic atrophy suggesting that the
defect was in the thymic environment [38, 39]. Immune re-
juvenation by a serum based factor is therefore ruled out as
an option but the idea of rejuvenating the peripheral
immune system by the adoptive transfer of blood from
younger to older individuals has a long history. In the early
1920’s Prof A.A. Bogdanov tested the hypothesis that the
transfusion of blood from young into older individuals may
rejuvenate the latter. He experimented on himself, accept-
ing transfused blood on up to 11 occasions, before the 12th
transfusion killed him in 1928 [40].
Half a litre of blood (500 ml) is the amount normally
donated for transfusion and this amount of blood will con-
tain approximately 7.5 × 108 T cells. In individuals aged 20
to mid 30’s approximately 50% or more of these cells will
be naïve and the rest memory cells. It would seem feasible
to collect this amount of blood and extract the leukocytes
on a regular basis and then store them in ampoules in li-
quid nitrogen until the individual becomes much older.
The memory cells will have a repertoire dependent on the
pathogens and antigens already encountered and so should
be slightly more restricted in terms of its diversity than the
naïve T cell population. The latter should contain recent
thymic emigrants and so have a diverse receptor repertoire.
In older individuals age related changes in both the per-
ipheral T and B pool of cells include the presence of holes
in the antigen specific receptor repertoire which conse-
quently is diminished and the presence of lymphocytes at
or close to their limit of replication. Re-transfusion of leu-
kocytes at a later stage of life could provide a means of
combatting both of these problems. There are of course
issues around how many cells to transfuse back into a re-
cipient, whether this number would integrate easily into
the indigenous population and whether the receptors for
specific pathogens would be present in the transfused
lymphocytes. Preliminary answers to these questions have
been provided by animal work [41], but more work is
needed on human volunteers to determine these parame-
ters. Despite this, several companies have grown up
offering a service for individuals to collect their leukocytes
early in their lifespan and store them in lymphocytes in li-
quid nitrogen for a prolonged period so that they can be
reinfused at later date.
Interleukin 7
Interleukin 7 (IL-7) is a type 1 short chain cytokine pro-
duced by the stromal cells of primary and secondary
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lymphoid organs which binds to a cell surface receptor
composed of an IL-7 specific alpha chain (CD127) and a
common gamma chain (CD132). The latter is termed
common since it is used as one of the receptor chains
for cytokines IL-2, 4, 9, 15 and 21 [42]. Expression of
CD127 and CD132 together are found at several stages
of the T cell development pathway from early progeni-
tors to memory cells. At the early intrathymic stages of
the T cell pathway the IL-7:IL-7R interaction is respon-
sible for ensuring cell survival [43] may be responsible
for generating T cell receptor diversity [44] and is associ-
ated with clonal expansion of mature thymocytes prior
to their export to the naïve T cell pool [45]. In peripheral
T cells the IL-7 ligand receptor interaction is mainly as-
sociated with clonal maintenance through ensuring cell
survival and proliferation in both the naïve and memory
T cell pools [46]. The potential for IL-7 to act as an im-
mune rejuvenating agent came from initial studies by
Bhatia et al. [47] on young mice treated for prolonged
periods with anti-IL-7 antibody. These mice showed se-
vere thymic atrophy and a decline in thymic cellularity
similar to that seen in older animals. Treatment of old
mice with IL-7 could reverse age-related atrophy of the
thymus, leading to a restoration of thymic output and an
improvement in peripheral T cell function [43, 48]. One
striking feature of using IL-7 to reverse thymic atrophy
was the importance of the quantity of IL-7 present in
the thymus as shown by experiments in which three
lines of transgenic mice were generated in which the IL-
7 gene was placed under the control of an lcx promoter.
Each line produced different amounts of IL-7 and the
line which produced the most (termed TgB) showed
lower levels of thymocytes numbers when compared
with wild type controls and were found to have a bottle-
neck in differentiation at the early stage of T cell devel-
opment [49]. Later work suggest that high levels of IL-7
antagonise Notch signalling and as such impact on the
choice of T versus B cell lineage by stem cells in the thy-
mus [50]. Rejuvenation of immunity in old female rhesus
macaques treated with recombinant simian IL-7 prior to
vaccination with influenza showed an increase in thymic
output and higher haemagglutinin titres in treated
animals compared to saline treated controls [51]. The
first clinical trial using IL-7 examined the therapeutic ef-
fects of IL-7 administered to humans with metastatic
cancer [52]. A more recent placebo controlled double
blind phase IIa trial in patients with lymphopaenic
metastatic breast cancer [53], some of whom received
recombinant IL-7 as part of their treatment regimen re-
ported encouraging results with IL-7 inducing a signifi-
cant increase in T cell numbers when delivered before
chemotherapy. In another study on HIV infected pa-
tients who were also receiving antiviral therapy the data
suggest that repeated cycles of recombinant human IL-7
were tolerated quite well by the recipients and sustained
T cell restoration was seen in the majority of the partici-
pants of the study [53]. To date no trial has reported on
the treatment of healthy older individuals who have re-
ceived IL-7 therapy.
Surgical or chemical castration
Early work on rodents showed that surgical castration
could lead to reversal of the age associated atrophy seen
in the thymus [54, 55] although this has been reported
to be transitory [56]. Chemical castration using
luteinizing hormone releasing hormone agonists have
been shown to be effective in inducing thymic regrowth
in old rodents [57] and in old primates [58] through a
mechanism which may involve the upregulation of
Delta-like 4 a Notch ligand crucial for T cell differenti-
ation [59]. Experiments in humans suggest that this
might be an attractive approach to improve immunity in
older males [60, 61], however the side effects associated
with the treatment may mitigate against this choice of
approach.
Keratinocyte growth factor
Keratinocyte Growth Factor (KGF) is a member of the
fibroblast growth factor family, a family which contains
secreted proteins which signal to receptor tyrosine ki-
nases and intracellular non-signalling proteins which act
as co-factors for voltage gated calcium channels [62].
KGF is the 7th member of this family and a secreted sig-
nalling molecule which interacts with its receptor
expressed on thymic epithelial cells and induces the
proliferation of thymic epithelial cell progenitors and
mature epithelial cells in fetal thymic organ cultures
[63]. Early experiments in murine system suggested that
the subcutaneous administration of KGF to mice for 3
consecutive days at 5 mg/Kg per day enhanced thymo-
poeisis for almost 2 months. Moreover the treatment
restored thymopoeisis in old mice [64]. These results
prompted experiments in primates which were reconsti-
tuted with CD34+ peripheral blood progenitor cells after
irradiation. Animals receiving treatment with KGF
showed increased frequencies of naïve T cells in their
lymph nodes compared with controls and more cells
recognised as recent thymic emigrants. In addition, KGF
treated animals preserved their thymic architecture up
to at least 12 months after the reconstitution [65].
Palifermin is a recombinant form of KGF of bacterial
origin which has been used to treat patients receiving
chemotherapy or radiation therapy to stimulate the
growth of cells in the mucosal barrier. The positive non-
human primate results prompted experiments using
Palifermin on patients with HIV-1 infection who were
receiving antiretroviral therapy. The hypothesis was that
poor CD4 levels in these patients was due to reduced
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thymic function and treatment with Palifermin should
improve the blood profile of CD4 cells in these patients.
However a randomised double blind placebo controlled
trial in HIV infected patients receiving ART [66]
revealed no significant change in either the numbers of
recent thymic emigrants, naïve cell numbers or thymic
size. The dose range used in these studies was from 20
to 60μg/Kg which is considerable less than the 5 mg/Kg
given to the mice in the original model and may be the
reason why no change was seen alternatively it is pos-
sible that the structure of the thymus was such that it
was irreparable within the time frame of the experiment.
Methods of assessment
To illustrate the problems associated with assessing
overall immunity let us consider the example of blood
pressure management. Years of gathering and analysing
data from blood pressure measurement has enabled phy-
sicians to derive a normal range for blood pressure
values for specific ages and/or specific health status.
Thus different thresholds have been tailored according
to the best risk/benefit ratio to initiate lowering blood
pressure drugs for robust, frail and terminally ill individ-
uals. Specific target values under treatment have been
also personalized [67]. No such scheme currently exists
for the immune system. Moreover, the challenge to face
with the immune system is it’s degree of complexity and
predicting individual immune capacity and responsive-
ness to specific antigen using a single and robust
method able to distinguish between a robust, frail and
deficient system would be very challenging [68].
Using vaccine response as a direct method of assessment
The assessment of an individual immune responsiveness
by confronting the immune system with common or
new vaccine antigens and hence quantifying the quality
of the immune functioning in its whole is a desirable
challenge. For example, the response to influenza vac-
cine is blunted in older people so one method of deter-
mining the effectiveness of a rejuvenation/restoration
therapy has been to carry out randomised clinical trials
comparing a treated aged group with a placebo treated
control group and assessing the difference in the titre of
the hemagglutination inhibition antibody levels. This ap-
proach was used successfully in the rapalogue trials [28],
but has the drawback that large numbers of individuals
have to be recruited for each arm to ensure statistically
significant results are achieved.
Longitudinal studies in which the same individual is
followed and tested before and after treatment may ap-
pear more preferable but has the problem in that if
vaccination is used as an assay system it would have to
be given before and the after the treatment. This may
prove a problem especially when the repeat vaccination
is against previously used strains because high pre-
vaccination hemagglutination antibody inhibition titres
because the history of previously encountered influenza
subtypes impacts the ensuing immune response [69–71].
Equally well, with other vaccines such as pneumococ-
cal polysaccharides vaccines subsequent repetitive
vaccination would fail to show benefit because of the
hyporesponsiveness [72] seen on revaccination. Another
option is to choose to issue the participants with illness
diaries which monitor the number of infections during
the period of the study and also their duration [73].
Compliance is often a factor with this approach as is
veracity. Subjective assessment whilst sometimes neces-
sary may not be optimal which is why many have chosen
a more objective approach and taken to using indirect
methods of assessment.
Indirect methods of assessment
Clinicians can have access to a large battery of biological
tests. They include complete blood counts, lymphocyte
subsets, serum immunoglobulin levels and the presence
of specific antibodies, none of which could be used to
assess immune rejuvenation satisfactorily. This is princi-
pally because these values can be similar in individuals
who are immune competent and those who provide a
less than adequate response. Approaches to identifying
improvements in global immunity have included meas-
uring change in the numbers of recent thymic emigrants
[51], the presence of increased numbers of naïve
lymphocytes or changes in subsets cells at different
stages of differentiation [74], cutaneous skin responses
[75] or changes in the parameters [76] of the immune
risk phenotype [77].
Conclusion
The issue at the core of the question about whether we
can rejuvenate the immune response is one of measure-
ment. We currently have no method of measuring the
overall immune capacity of an individual. Often this
measure is through clinical observation that the patient
has infections which are unusual, persistent, or alterna-
tively which have become recurrent or have progressed
to becoming systemic. These are often subjective assess-
ments and there are no objective laboratory based tests
which provide a measure of overall immune capacity.
This despite a long history of assays which quantify a
response to an antigen through demonstrating the anti-
body titre or assessing an individual T cell specific
response to a viral glycoprotein. We only know the level
of response associated with protection from a disease for
a small handful of pathogens.
There is no normal range for immune activity and
until we can provide a method for measuring this activ-
ity we have firstly no means of determining whether an
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individual is in need of therapy and secondly what the
effect of that rejuvenation therapy may be. The complex-
ity of the problem is also added to by the identification
that a successful immune response is not only depend-
ant on producing enough specific antibody of effector T
cells. Susceptibility to disease is also reliant on a number
of innate immune system barriers, such as the integrity
of the skin, the flushing action of tears, saliva or urine,
the action of ciliated epithelium and mucous as well as
the response from neutrophils, macrophages and natural
killer cells.
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